PREVENTION OF HYPOGLYCAEMIA IN A PATIENT WITH PANCREATIC MICROADENOMATOSIS BY A LONG‐ACTING SOMATOSTATIN ANALOGUE SMS 201‐995
- 1 October 1987
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 27 (4) , 469-473
- https://doi.org/10.1111/j.1365-2265.1987.tb01175.x
Abstract
SUMMARY: Acute suppression of insulin secretion from pancreatic insulinomas by long‐acting somatostatin analogue SMS 201‐995 has been documented. We report the chronic use of the drug in a patient with persistent hypoglycaemia due to benign pancreatic microadenomatosis with satisfactory control of plasma glucose level and reduction of insulin production. There was no tachyphylaxis or untoward side‐effect noted during the 6‐month treatment period.This publication has 6 references indexed in Scilit:
- Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin)Acta Endocrinologica, 1986
- Malignant Insulinoma: Effects of a Somatostatin Analog (Compound 201-995) on Serum Glucose, Growth, and Gastro-Entero-Pancreatic HormonesAnnals of Internal Medicine, 1985
- Multiple subcutaneous injections of somatostatin induce tachyphylaxis of the suppression of plasma insulin, but not glucagon, in the ratRegulatory Peptides, 1982
- INHIBITION OF INSULIN SECRETION BY SOMATOSTATINThe Lancet, 1973
- Current Surgical Management of Functioning Islet Cell Tumors of the PancreasAnnals of Surgery, 1973
- Über einige Geschwulstbildungen des PankreasVirchows Archiv, 1925